UnknownPhase 1/2

Establishment of Clinical Basis for Hematopoietic Growth Factors Therapy in Brain Injury

South Korea60 participantsStarted 2011-07-05

Plain-language summary

The purpose of our study is to determine the safety and efficacy of the combination of erythropoietin (EPO) and granulocyte-colony stimulating factors (G-CSF) in patients with neurological diseases. To be specific, our clinical study is expected that the combination injection of EPO and G-CSF shows neurotrophic and neuroprotective effects by facilitating endogenous repair process in patients with neurological diseases including stroke, cerebral palsy, or atypical parkinsonism. Therefore, we will apply our original treatment technique in patients with neurological diseases, which is expected to overcome current ethical and technical limitations of less evidenced functional recovery, hematological changes, and side effects. Eventually, We will establish a comprehensive clinical background about neurotrophic and neuroprotective effects of this hematopoietic growth factors therapy.

Who can participate

Age range20 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Over 20 years old * Voluntary participants * Neurological diseases including stroke, cerebral palsy, or atypical parkinsonism, at least 3 months after their onset * Participants who got previous EPO+GCSF injection at least 6 months ago. Exclusion Criteria: * Under 20 years old * Participants who can not voluntarily consent * Encephalopathy including brain tumor and infection * Warfarin (coumadin) medications * Leukopenia, Thrombocytopenia, Polycythemia * Malignant diseases, Malignant hypertension, Myeloproliferative disorder, Septic embolism, Hyperkalemia * Hepatic or Renal dysfunction, Serum creatinine\>3mg/dl * Allergic reactions against to exogenous EPO and G-CSF * Involved in a exclusion criteria for MRI test * A women who is pregnant or on breast feeding * Body temperature over 38°C * Blood pressure over 140/90 mmHg at pre-treatment * Blood pressure over 160/100 mmHg during intervention * Hb \> 15 g/dL at pre-treatment * Hb \> 17 g/dL during intervention * Pneumonia detected by X-ray test * Recurrent history of aspiration pneumonia

What they're measuring

Vital Sign

Timeframe: 5th day, 30th day during a cycle, and 6 months after pretest

Hematological Test

Timeframe: 5th day, 30th day during a cycle, and 6 months after pretest

Chest and Heart Evaluation

Timeframe: at pre-treatment and 6 months after pretest

Trial details

NCT IDNCT02018406

SponsorYonsei University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-12

Contact for this trial

Sung-Rae Cho, MD

82-2-2228-3715 srcho918@yuhs.ac